187 related articles for article (PubMed ID: 33850270)
1. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.
Li JKM; Wang LL; Wong CYP; Chiu PKF; Teoh JYC; Kwok HSW; Leung SCH; Wong SH; Tsui SKW; Ng CF
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1063-1072. PubMed ID: 33850270
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
3. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
4. Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
Shin D; Shim SR; Kim CH
PLoS One; 2020; 15(6):e0234264. PubMed ID: 32542009
[TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
6. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
Dean JP; Sprenger CC; Wan J; Haugk K; Ellis WJ; Lin DW; Corman JM; Dalkin BL; Mostaghel E; Nelson PS; Cohen P; Montgomery B; Plymate SR
J Clin Endocrinol Metab; 2013 May; 98(5):E820-8. PubMed ID: 23533230
[TBL] [Abstract][Full Text] [Related]
7. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study.
Lycken M; Drevin L; Garmo H; Larsson A; Andrén O; Holmberg L; Bill-Axelson A
Scand J Urol; 2020 Jun; 54(3):208-214. PubMed ID: 32338176
[No Abstract] [Full Text] [Related]
8. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
9. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy use with post-prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria.
Ong WL; Foroudi F; Evans S; Millar J
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):124-130. PubMed ID: 30295411
[TBL] [Abstract][Full Text] [Related]
12. Gut environment changes due to androgen deprivation therapy in patients with prostate cancer.
Kure A; Tsukimi T; Ishii C; Aw W; Obana N; Nakato G; Hirayama A; Kawano H; China T; Shimizu F; Nagata M; Isotani S; Muto S; Horie S; Fukuda S
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):323-330. PubMed ID: 35418210
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
14. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
Gonzalez BD; Jim HSL; Small BJ; Sutton SK; Fishman MN; Zachariah B; Heysek RV; Jacobsen PB
Support Care Cancer; 2016 May; 24(5):2201-2207. PubMed ID: 26563183
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
16. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.
Bo JJ; Zhang C; Zhang LH; Liu P; Sha JJ; Lv JW; Liu DM; Huang YR; Li Z
Asian J Androl; 2011 Nov; 13(6):833-7. PubMed ID: 21785444
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
Kim M; Song C; Jeong IG; Choi SK; Park M; Shim M; Kim YS; You D; Hong JH; Kim CS; Ahn H
BMC Cancer; 2018 Mar; 18(1):271. PubMed ID: 29523103
[TBL] [Abstract][Full Text] [Related]
19. Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study.
Jin D; Jin K; Chen B; Zhou X; Yuan Q; Zhang Z; Wei Q; Qiu S
Chin Med J (Engl); 2022 Apr; 135(7):820-827. PubMed ID: 35234695
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]